First nine months
|
Nine months 2004 |
Nine months 2003 |
% Change | |||
|
USD m |
% of sales |
USD m |
% of sales |
USD |
lc[1] |
Sales |
20 669 |
|
18 134 |
|
14 |
9 |
Pharmaceutical sales |
13 528 |
|
11 641 |
|
16 |
11 |
Consumer Health sales |
7 141 |
|
6 493 |
|
10 |
5 |
Operating income |
5 005 |
24.2 |
4 283 |
23.6 |
17 |
|
Net income |
4 389 |
21.2 |
3 656 |
20.2 |
20 |
|
Basic earnings per share/ADS |
USD 1.79 |
|
USD 1.48 |
|
21 |
|
|
|
|
|
|
|
|
Third quarter |
|
|
|
|
|
|
|
Q3 2004 |
Q3 2003 |
% Change | |||
|
USD m |
% of sales |
USD m |
% of sales |
USD |
lc |
Sales |
7 057 |
|
6 210 |
|
14 |
9 |
Pharmaceutical sales |
4 646 |
|
4 041 |
|
15 |
11 |
Consumer Health sales |
2 411 |
|
2 169 |
|
11 |
7 |
Operating income |
1 717 |
24.3 |
1 469 |
23.7 |
17 |
|
Net income |
1 547 |
21.9 |
1 277 |
20.6 |
21 |
|
Basic earnings per share/ADS |
USD 0.63 |
|
USD 0.52 |
|
21 |
|
[1] lc - Local currencies
Please find full press release under the following link:
http://dominoext.novartis.com/NC/NCPRRE01.nsf
http://dominoext.novartis.com/NC/NCPRRE01.nsf
Contacts:
John Gilardi
Novartis Global Media Relations
Tel +41 61 324 3018 (direct)
or +41 79 596 1408 (mobile)
john.gilardi@group.novartis.com
Novartis Global Media Relations
Tel +41 61 324 3018 (direct)
or +41 79 596 1408 (mobile)
john.gilardi@group.novartis.com
Kim Fox
Novartis Pharma Communications
+1 862 778 7692 (direct)
+1 917 415 2425 (mobile)
kim.fox@pharma.novartis.com
Novartis Pharma Communications
+1 862 778 7692 (direct)
+1 917 415 2425 (mobile)
kim.fox@pharma.novartis.com